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Summary
Recent studies have revealed that ARID1A is frequently mutated across a wide variety of human
cancers and also has bona fide tumor suppressor properties. Consequently, identification of
vulnerabilities conferred by ARID1A mutation would have major relevance for human cancer.
Here, using a broad screening approach, we identify ARID1B, a related but mutually exclusive
homolog of ARID1A in the SWI/SNF chromatin remodeling complex, as the number one gene
preferentially required for the survival of ARID1A-mutant cancer cell lines. We show that loss of
ARID1B in ARID1A-deficient backgrounds destabilizes SWI/SNF and impairs proliferation.
Intriguingly, we also find that ARID1A and ARID1B are frequently co-mutated in cancer, but that
ARID1A-deficient cancers retain at least one ARID1B allele. These results suggest that loss of
ARID1A and ARID1B alleles cooperatively promotes cancer formation but also results in a unique
functional dependence. The results further identify ARID1B as a potential therapeutic target for
ARID1A-mutant cancers.
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tTo search for specific dependencies created by ARID1A mutation, we utilized data from
Project Achilles, a large-scale project focused on identifying essential genes in a wide panel
of cancer cell lines using genome-scale loss-of-function genetics1. We compared 18
ARID1A-mutant and 147 cell lines wildtype for ARID1A (hereafter referred to as wildtype).
Of 9,050 genes interrogated, ARID1B scored as the top candidate preferentially required for
the growth of ARID1A-mutant cancer cell lines (p=7.366×10−6, FDR<0.001) (Fig. 1a, Fig.
S1a). Vulnerability to ARID1B depletion was even more pronounced in the large subset of
cell lines that contained inactivating ARID1A mutations (rather than missense mutations)
(Fig. 1b), suggesting that ARID1B is specifically essential for cell lines lacking ARID1A
(see supplementary discussion). To further evaluate this finding, we examined effects of the
individual ARID1B shRNAs. Three of the four ARID1B shRNAs passed the Achilles
quality control metrics2. These scored #1 (p=1.211×10−6, FDR<0.001), #4 (p=1.211×10−6,
FDR<0.001), and #11 (p=1.816×10−5, FDR=0.090) of the 54,020 shRNAs in the screen. We
confirmed ARID1B as a vulnerability by knocking it down in two cell lines that contained
ARID1A-inactivating mutations, OVISE and TOV21G, and two ARID1A wildtype lines,
ES-2 and 293T (Fig. 1c, Fig. S1b). Proliferation (Fig. 1d) and colony formation (Fig. 1e)
were impaired in ARID1A-mutant cells but not in wildtype cells.
ARID1B and ARID1A are 60% identical, have been reported to have opposing functions in
cell cycle arrest, and are mutually exclusive since individual SWI/SNF chromatin
remodeling complexes can contain either ARID1A or ARID1B, but not both3. To
investigate the relationship between ARID1A and ARID1B in cancer, we asked whether an
ARID1B-containing SWI/SNF complex was present in ARID1A-mutant cells.
Immunoprecipitation of the SMARCC1 (BAF155) core subunit of the SWI/SNF complex4
resulted in co-precipitation of ARID1B and other SWI/SNF subunits in both wildtype and
ARID1A-mutant cells, indicating that intact ARID1B-containing complexes are present (Fig.
S2a–b) in both wildtype and ARID1A-mutant cells.
We next sought to determine whether ARID1B loss affects the composition of the SWI/SNF
complex in ARID1A-mutant cancer cells. Knockdown of ARID1B in wildtype cell lines had
no effect on the expression of other SWI/SNF complex subunits (Fig. 2a, Fig. S2c) or upon
their incorporation into the complex (Fig. 2a, Fig. S2c). However, depletion of ARID1B in
ARID1A-mutant cells resulted in dissociation of the core catalytic ATPase subunit
SMARCA4 (BRG1) and reduced incorporation of several other subunits (Fig. 2a). Protein
levels of core subunits such as SMARCA4, SMARCC2, and SMARCB1 were also
decreased, particularly in the TOV21G line (Fig. 2a), while the mRNA levels were largely
unaffected (Fig. S3), suggesting post-translational loss of these proteins.
To further investigate how ARID1B loss affects assembly of the SWI/SNF complex, we
performed a sucrose sedimentation assay on cells treated with either control shRNA or
ARID1B shRNA. Consistent with the co-immunoprecipitation results, an intact 2 MDa SWI/
SNF complex is observed in ARID1A-mutant cells treated with control shRNA (Fig. 2b, full
figure in Fig. S4–5) and in wildtype cells treated with either control or ARID1B shRNA
(Fig. S6). In contrast, knockdown of ARID1B in ARID1A-mutant cells eliminated the intact
SWI/SNF complex (Fig. 2b; additional subunits shown in Fig. S4–5), indicating that in
human ARID1A-mutant cancer cell lines, the presence of ARID1B is essential for formation
or stabilization of an intact SWI/SNF complex. Despite ARID1A/ARID1B and PBRM1
having been reported to exist in mutually exclusive versions of the SWI/SNF complex5, our
findings are consistent with a more recent publication, which found that these subunits can
co-exist6, as PBRM1 association with smaller complexes was substantially affected by the
combined loss of ARID1A/B (Fig S4–5). As the SWI/SNF complex binds up to one-third of
all genes7 and several members of the SWI/SNF complex are essential in mouse
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tdevelopment8–10 and for survival of many cell lineages11,12, loss of an intact SWI/SNF
complex would be predicted to be incompatible with cell viability.
In order to further validate the identification of ARID1B as a vulnerability in ARID1A-
mutant human cancer, we sought to investigate whether inactivation of Arid1a creates a
dependence upon Arid1b using primary MEFs conditional for Arid1a 13. Deletion of Arid1a
or knockdown of Arid1b individually had only moderate effects on proliferation, while
combined loss led to substantial impairment (Fig. S7a). We similarly observed that loss of
Arid1a or Arid1b alone had only modest effects on the composition of the complex (Fig.
2c), while loss of both led to dissociation and degradation of Smarca4 and substantial
reductions in stability and incorporation of many other SWI/SNF subunits (Fig. 2d). Again,
the reduced protein levels were not due to changes in transcription (Fig. S7b). Finally,
sucrose sedimentation assay showed that loss of Arid1a and Arid1b in MEFs eliminated the
intact SWI/SNF complex (Fig. 2d and Fig. S7c).
Collectively, these findings demonstrate a synthetic lethal relationship between this mutually
exclusive pair of SWI/SNF subunits. Notably, however, ARID1B has also been reported
mutated in human cancers3,14, and has been found to be mutant in some of the same types of
cancer as ARID1A, such as neuroblastoma14. Since we found ARID1B knockdown to impair
the growth of ARID1A-mutant cell lines, we initially hypothesized that mutations in ARID1A
and ARID1B would be mutually exclusive. Surprisingly, we found that ARID1A and
ARID1B mutations co-occur in both cancer cell lines and primary tumors. Using data from
cell line sequencing 15,16 we found that 38% of 34 ARID1A-mutant lines also contained
ARID1B-inactivating mutations16 (Supplementary Table 1, p<1×10−6). Notably, all lines
retained at least one allele of either ARID1A or ARID1B, suggesting that retention of at least
one ARID1 allele may be essential for survival. This finding also held true in primary cancer
samples. We found that of the 297 ARID1A-mutant primary cancer samples cataloged in the
cBio Portal for Cancer Genomics17,18, 30 (10.1%) also contained ARID1B mutations
(p=1.07×10−7), significantly higher than the 3% rate in ARID1A-wildtype tumors.
The co-occurrence of ARID1A and ARID1B mutations raises the possibility that the
synthetic lethality relationship could be caused simply by the high frequency of ARID1B
mutations in ARID1A-mutant cancer cell lines. To evaluate this possibility, we removed all
ARID1B-mutant cell lines and conducted a revised class comparison in which four ARID1B-
wildtype, ARID1A-mutant cell lines were compared to 49 cell lines wildtype for both
ARID1A and ARID1B. ARID1B still scored number four out of 9,000+ genes
(p=7.154×10−4), indicating that the synthetic lethality between ARID1A and ARID1B is a
result of ARID1A mutation and not co-occurring ARID1B mutations.
In this report, we show that inactivating mutations in ARID1A, frequent across a wide
variety of cancers, create a dependency upon ARID1B (Fig. 2e). It is notable that the
number one vulnerability in ARID1A-mutant cell lines is another member of the SWI/SNF
complex. We previously showed that cancer formation in the absence of the SWI/SNF
subunit SMARCB1 does not result from SWI/SNF inactivation but rather that oncogenesis
was dependent upon the activity of the residual SWI/SNF complex19. At that time we
speculated that, much like the concept of oncogene addiction, targeting the aberrant residual
SWI/SNF complex might theoretically be an effective therapeutic approach for SMARCB1-
mutant cancers. Our present study, which surveyed 9,050 genes, reveals the role of the
residual complex in the growth of ARID1A-deficient cancers and also identifies a specific
subunit as a relative vulnerability. This principle may have broad applicability to SWI/SNF-
mutant cancers as Oike et al recently showed that SMARCA2, a paralog of SMARCA4, was
essential in SMARCA4-mutant cancers20.
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tTogether, our findings may suggest that partial loss of ARID1 function via mutation of
ARID1A alleles or, less frequently, ARID1B alleles can drive cancer growth but at the same
time create a specific vulnerability compared to non-mutant cells. This suggests ARID1B as
a potential therapeutic target for cancers that contain inactivating ARID1A mutations. Recent
examples have demonstrated the feasibility and efficacy of targeting chromatin regulators
such as BRD421,22 as well as other non-enzymatic proteins such as BCL-223 and molecules
previously found difficult to target such as RAS24. ARID1B could potentially be targetable
through its E3 ubiquitin ligase interaction25. Additionally, novel approaches using small
stabilized peptides have recently been shown capable of disrupting association of EZH2
with its chromatin remodeling complex26. Analogous approaches may now be considered
for targeting ARID1B.
Online Methods
Achilles Analysis
To find genes that are preferentially essential in mutant cell lines, we used the GenePattern
module PARIS (http://www.broadinstitute.org/cancer/software/genepattern) using the
default parameters except quality, which was changed to final. The gene-level Achilles
dataset v2.4 was used as a data file (www.broadinstitute.org/achilles) (file name:
Achilles_QC_v2.4_rnai.Gs.gct). The classifier files were generated using the gene mutation
status from the Cancer Cell Line Encyclopedia (www.broadinstitute.org/ccle). Cell lines
without hybrid capture sequencing data were removed from the analysis. The mutational
status of ARID1A was annotated for 165 of the 216 cell lines in the Achilles dataset, and as a
result, these 165 cell lines were used in the class comparisons.
Cell Culture
TOV21G (CRL 11730), ES-2 (CRL-1987), and 293T (CRL-3216) cell lines were purchased
from ATCC. OVISE cells were obtained from William Hahn’s laboratory. Mouse
Embryonic Fibroblasts (MEFs) were generated as described previously27. Cells were
transduced with shRNAs and selected with puromycin for 48–72 hours before seeding for
MTT or colony formation assays. MTT assays were conducted with a Cell Proliferation Kit
(Roche). Colony formation assays were conducted by staining cells for 20 minutes with
crystal violet staining solution (0.05% Crystal Violet, 1% Formaldehyde, 1% PBS, 1%
methanol).
shRNA-mediated knockdown of ARID1B
ARID1B shRNAs were obtained from the RNA interference (RNAi) screening facility at the
Dana-Farber Cancer Institute and were lentivirally transduced into OVISE, TOV21G, ES-2,
and 293T cells. ARID1B and non-silencing control shRNAs are in the pLKO.1 lentiviral
expression vector backbone. Target sequences for shRNAs are available upon request.
Density Sedimentation Analysis
Nuclear extract (1 mg) was diluted in 300 μl of 0% sucrose RIPA buffer and carefully
overlaid onto a 12 ml 20%–50% sucrose (in RIPA buffer) gradient prepared in a 14ml
14×95 mm polyallomer centrifuge tube (Cat. #331374, Beckman Coulter). Tubes were
placed in an SW-40 Ti swing bucket rotor and centrifuged at 4°C for 16 hours at 40,000
rpm. Fractions (0.5 ml) were collected and used in gel electrophoresis and subsequent
Western blotting analyses.
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tImmunoblots and co-immunoprecipitation experiments
Whole cell extracts for immunoblotting were prepared by incubating cells on ice in 1%
NP-40 lysis buffer (50 mM Tris-HCL pH 7.4, 5mM EDTA, 12% Glycerol, 50mM NaCl, 1%
NP-40) plus protease inhibitors (Complete, Mini, EDTA-free. Roche: 11836170001) for 30
minutes. Supernatants were collected following a brief spin (10 min.) at 17900 r.c.f. to
separate cellular debris in a 4° C centrifuge. Protein concentrations were determined using
the Bradford reagent (Biorad). SDS-polyacrylamide gel electrophoresis was used to separate
proteins, which were subsequently transferred to PVDF membranes (Millipore). ARID1B
antibody (Abcam: ab54761) was used to detect efficient knockdown.
Nuclear extracts for immunoprecipitation were prepared using the NE-PER Nuclear and
Cytoplasmic Extraction Kit (Thermo Scientific: 78833). Nuclear extracts were diluted with
RIPA buffer (1 mg/ml, with protease inhibitors and DTT). Each IP was incubated with
indicated antibodies overnight at 4° C. Protein G Dynabeads (Life Technologies: 10004D)
were added and incubated at 4° C for 3 hrs. Beads were then washed three times with RIPA
buffer and resuspended in reducing SDS gel loading buffer. Antibodies used in the
immunoprecipitation and immunoblots are: SMARCC1/BAF155 (Santa Cruz: 9746);
ARID1A (Bethyl Laboratories: A301-041A); PBRM1 (Bethyl Laboratories: A301-591A);
SMARCA4 (Santa Cruz: sc17796); SMARCC2/BAF170 (Bethyl Laboratories:
A301-039A); SMARCD1/BAF60A (Bethyl Laboratories: A301-595A); SMARCE1/BAF57
(Bethyl Laboratories: A300-810A); ACTL6A/BAF53A (Bethyl Laboratories: A301-391A);
ACTIN (Cell Signaling Technology: 5125).
RNA purification and RT-qPCR
Total RNA was extracted using Trizol reagent (Invitrogen) following the manufacturer’s
instructions. 2 µg of total RNA was reverse-transcribed into first-strand cDNA using
oligo(dT)20 primers and the SuperScript III Reverse Transcriptase (Invitrogen). RT-qPCR
was performed on the ViiA 7 Real-Time PCR System (Life Technologies) using SYBR
Select Master Mix (Life Technologies). Reactions were performed in triplicate, and gene
expression was normalized to GAPDH. Error bars represent SD of mean expression.
Cell Line Sequencing
Cell lines were sequenced as previously described15. Cell line sequencing data and the data
from the Cancer Cell Line Encyclopedia16 were used to identify cell lines with co-occurring
mutations of ARID1A and ARID1B.
Statistical Significance of Mutation Overlap
To evaluate the statistical significance of the overlap of ARID1A and ARID1B mutations,
the probability of observing at least n12 cell lines with both mutations was estimated under
the null hypothesis that these two mutations are independent. For that, given n1 cell lines
with ARID1A and n2 cell lines with ARID1B mutations and n12 cell lines with both
mutations the following simulation was run: n1 cell lines were randomly picked with the
probability for each cell line being selected set relative to its mutation rate and assigned
mutation ‘A’ to these cell lines. Next, n2 cell lines were similarly selected and assigned
mutation ‘B’ to those cell lines and then the number of cell lines with both mutations ‘A’
and ‘B’ was counted. This process was repeated many times to estimate the probability of
observing n12 cell lines or more with both mutations.
For primary cancer samples, a contingency table was formed consisting of the counts for all
the four possibilities of ARID1A or ARID1B mutation status. The Fisher’s exact test was
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tused to calculate the statistical significance of the overlap of ARID1A and ARID1B
mutations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. ARID1B is a specific vulnerability in ARID1A-mutant cancer cell lines
(a) Rank list of vulnerabilities identified by screen of Achilles platform cell lines. ARID1B
is the #1 gene preferentially essential for the growth of ARID1A-mutant cancer cell lines as
compared to wildtype cancer cell lines.
(b) Effects of ARID1B shRNAs across cell lines in the Achilles screen. Negative values
indicate growth inhibition while positive values reflect growth enhancement. In the top
panel, cell lines with any identified ARID1A mutation compared to the reference genome are
indicated in red. In the bottom panel, only those cell lines with clear inactivating mutations
in ARID1A are shown in red.
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t(c) Immunoblots showing the results of two independent shRNAs targeting ARID1B in
ES-2 and 293T (ARID1A-wildtype lines) and in OVISE, and TOV21G (ARID1A-mutant
lines).
(d) Proliferation of wildtype (ES-2 and 293T) and ARID1A-mutant (OVISE and TOV21G)
cell lines in response to two independent ARID1B shRNAs. * p<0.0002 **p<4×10−8
#p>0.05 ##p<0.05 Data are expressed as mean ± S.D.
(e) Colony formation in response to ARID1B knockdown in wildtype and ARID1A-mutant
cell lines.
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tFigure 2. ARID1B is required for the maintenance of an intact SWI/SNF complex in ARID1A-
mutant cancer cell lines and primary cells
(a) Immunoprecipitation of the SWI/SNF complex by SMARCC1 from the nuclear extract
of ES-2, OVISE, and TOV21G cells upon treatment with control shRNA or two independent
ARID1B shRNAs.
(b) Sucrose sedimentation (20−50%) assay of SWI/SNF complex from ARID1A-mutant
TOV21G cells treated with either control shRNA (top half) or ARID1B shRNA (bottom
half).
(c) Immunoprecipitation of the SWI/SNF complex by Smarcc1 from the nuclear extract of
MEFs with indicated treatment.
Helming et al. Page 10
Nat Med. Author manuscript; available in PMC 2014 September 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t(d) Sucrose sedimentation (20−50%) assay of the SWI/SNF complex from the nuclear
extract of MEFs with indicated treatment: control shRNA treated MEFs (top half) or Arid1a
knockout (KO) and Arid1b knockdown (KD) MEFs (bottom half)
(e) Model: Inactivating mutations in ARID1A promote oncogenic transformation but also
create specific dependency on ARID1B. Inhibition of ARID1B in ARID1A-mutant cells
destabilizes the SWI/SNF complex and results in impaired cell growth.
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